ITIM-dependent negative signaling pathways for the control of cell-mediated xenogeneic immune responses

Xenotransplantation

Volumn 20, Issue 6, 2013, Pages 397-406

  Del Rio, Maria Luisa ^a   Seebach, Jörg D ^b   Fernández Renedo, Carlos ^a   Rodriguez Barbosa, Jose Ignacio ^a  

^a UNIVERSITY OF LEÓN   (Spain)

^b Leon Transplantation Regional Agency ^*  (Switzerland)

Author keywords

cellular rejection; co inhibitory receptors and ligands; immunoreceptor tyrosine based inhibitory motif; killer immunoglobulin like receptor; macrophages; NK cells; T cells; xenotransplantation

Indexed keywords

BELATACEPT; LIGAND;

B LYMPHOCYTE; CELL MEDIATED XENOGENEIC IMMUNE RESPONSE; CELLULAR IMMUNITY; CYTOTOXICITY; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNORECEPTOR TYROSINE BASED INHIBITION MOTIF; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; MACROPHAGE; MEDIATOR; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TRANSGENIC PIG;

CELLULAR REJECTION; CO-INHIBITORY RECEPTORS AND LIGANDS; IMMUNORECEPTOR TYROSINE-BASED INHIBITORY MOTIF; KILLER IMMUNOGLOBULIN-LIKE RECEPTOR; MACROPHAGES; NK CELLS; T CELLS; XENOTRANSPLANTATION;

ANIMALS; ANTIGENS, HETEROPHILE; GRAFT REJECTION; HUMANS; IMMUNITY, CELLULAR; IMMUNORECEPTOR TYROSINE-BASED ACTIVATION MOTIF; KILLER CELLS, NATURAL; MACROPHAGES; MODELS, IMMUNOLOGICAL; SIGNAL TRANSDUCTION; SUS SCROFA; TRANSPLANTATION IMMUNOLOGY; TRANSPLANTATION, HETEROLOGOUS;

EID: 84889607354     PISSN: 0908665X     EISSN: 13993089     Source Type: Journal    
DOI: 10.1111/xen.12049     Document Type: Review

References (79)

1. Auchincloss H Jr, Sachs DH,. Xenogeneic transplantation. Annu Rev Immunol 1998; 16: 433-470. (Pubitemid 28183372)
2. Bradley JA,. Overcoming the immunological barriers to xenotransplantation. Transplantation 1999; 68: 9-11. (Pubitemid 29352821)
3. Tisato V, Cozzi E,. Xenotransplantation: an overview of the field. Methods Mol Biol 2012; 885: 1-16.
4. Ekser B, Ezzelarab M, Hara H, et al. Clinical xenotransplantation: the next medical revolution? Lancet 2012; 379: 672-683.
5. Klymiuk N, Aigner B, Brem G, Wolf E,. Genetic modification of pigs as organ donors for xenotransplantation. Mol Reprod Dev 2010; 77: 209-221.
6. Schneider MK, Seebach JD,. Current cellular innate immune hurdles in pig-to-primate xenotransplantation. Curr Opin Organ Transplant 2008; 13: 171-177. (Pubitemid 351374256)
7. Scalea J, Hanecamp I, Robson SC, Yamada K,. T-cell-mediated immunological barriers to xenotransplantation. Xenotransplantation 2012; 19: 23-30.
8. del Rio ML, Lucas CL, Buhler L, Rayat G, Rodriguez-Barbosa JI,. HVEM/LIGHT/BTLA/CD160 cosignaling pathways as targets for immune regulation. J Leukoc Biol 2010; 87: 223-235.
9. Watanabe N, Gavrieli M, Sedy JR, et al. BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat Immunol 2003; 4: 670-679. (Pubitemid 36874444)
10. Han P, Goularte OD, Rufner K, Wilkinson B, Kaye J,. An inhibitory Ig superfamily protein expressed by lymphocytes and APCs is also an early marker of thymocyte positive selection. J Immunol 2004; 172: 5931-5939. (Pubitemid 38621192)
11. Oya Y, Watanabe N, Owada T, et al. Development of autoimmune hepatitis-like disease and production of autoantibodies to nuclear antigens in mice lacking B and T lymphocyte attenuator. Arthritis Rheum 2008; 58: 2498-2510.
12. Krieg C, Boyman O, Fu YX, Kaye J,. B and T lymphocyte attenuator regulates CD8+ T cell-intrinsic homeostasis and memory cell generation. Nat Immunol 2007; 8: 162-171. (Pubitemid 46152647)
13. Nishimura H, Nose M, Hiai H, Minato N, Honjo T,. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999; 11: 141-151. (Pubitemid 29428807)
14. del Rio ML, Buhler L, Gibbons C, Tian J, Rodriguez-Barbosa JI,. PD-1/PD-L1, PD-1/PD-L2, and other co-inhibitory signaling pathways in transplantation. Transpl Int 2008; 21: 1015-1028.
15. Barclay AN, Brown MH,. The SIRP family of receptors and immune regulation. Nat Rev Immunol 2006; 6: 457-464.
16. Yang YG,. CD47 in xenograft rejection and tolerance induction. Xenotransplantation 2010; 17: 267-273.
17. Ravetch JV, Lanier LL,. Immune inhibitory receptors. Science 2000; 290: 84-89.
18. Daeron M, Jaeger S, Du PL, Vivier E,. Immunoreceptor tyrosine-based inhibition motifs: a quest in the past and future. Immunol Rev 2008; 224: 11-43.
19. Blank U, Launay P, Benhamou M, Monteiro RC,. Inhibitory ITAMs as novel regulators of immunity. Immunol Rev 2009; 232: 59-71.
20. Veillette A, Latour S, Davidson D,. Negative regulation of immunoreceptor signaling. Annu Rev Immunol 2002; 20: 669-707. (Pubitemid 34293437)
21. Daeron M, Lesourne R,. Negative signaling in Fc receptor complexes. Adv Immunol 2006; 89: 39-86.
22. Vivier E, Nunes JA, Vely F,. Natural killer cell signaling pathways. Science 2004; 306: 1517-1519. (Pubitemid 39564941)
23. Rudd CE, Schneider H,. Unifying concepts in CD28, ICOS and CTLA4 co-receptor signalling. Nat Rev Immunol 2003; 3: 544-556. (Pubitemid 37328674)
24. Coggeshall KM, Nakamura K, Phee H,. How do inhibitory phosphatases work? Mol Immunol 2002; 39: 521-529. (Pubitemid 35341491)
25. Daeron M, Latour S, Malbec O, et al. The same tyrosine-based inhibition motif, in the intracytoplasmic domain of Fc gamma RIIB, regulates negatively BCR-, TCR-, and FcR-dependent cell activation. Immunity 1995; 3: 635-646.
26. Gorczynski RM,. CD200 and its receptors as targets for immunoregulation. Curr Opin Investig Drugs 2005; 6: 483-488. (Pubitemid 40613969)
27. Smith MJ, Hardy WR, Murphy JM, Jones N, Pawson T,. Screening for PTB domain binding partners and ligand specificity using proteome-derived NPXY peptide arrays. Mol Cell Biol 2006; 26: 8461-8474. (Pubitemid 44748579)
28. Mihrshahi R, Barclay AN, Brown MH,. Essential roles for Dok2 and RasGAP in CD200 receptor-mediated regulation of human myeloid cells. J Immunol 2009; 183: 4879-4886.
29. Zhang S, Phillips JH,. Identification of tyrosine residues crucial for CD200R-mediated inhibition of mast cell activation. J Leukoc Biol 2006; 79: 363-368. (Pubitemid 44831168)
30. Ljunggren HG, Karre K,. In search of the 'missing self': MHC molecules and NK cell recognition. Immunol Today 1990; 11: 237-244. (Pubitemid 20198988)
31. Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S,. Functions of natural killer cells. Nat Immunol 2008; 9: 503-510. (Pubitemid 351560519)
32. Vilches C, Parham P,. KIR: diverse, rapidly evolving receptors of innate and adaptive immunity. Annu Rev Immunol 2002; 20: 217-251. (Pubitemid 34293425)
33. Trowsdale J, Barten R, Haude A, et al. The genomic context of natural killer receptor extended gene families. Immunol Rev 2001; 181: 20-38. (Pubitemid 32703393)
34. Yang YG, Sykes M,. Xenotransplantation: current status and a perspective on the future. Nat Rev Immunol 2007; 7: 519-531. (Pubitemid 46987781)
35. Seebach JD, Comrack C, Germana S, et al. HLA-Cw3 expression on porcine endothelial cells protects against xenogeneic cytotoxicity mediated by a subset of human NK cells. J Immunol 1997; 159: 3655-3661. (Pubitemid 127482126)
36. Forte P, Baumann BC, Schneider MK, Seebach JD,. HLA-Cw4 expression on porcine endothelial cells reduces cytotoxicity and adhesion mediated by CD158a+ human NK cells. Xenotransplantation 2009; 16: 19-26.
37. Rouas-Freiss N, Goncalves RM, Menier C, Dausset J, Carosella ED,. Direct evidence to support the role of HLA-G in protecting the fetus from maternal uterine natural killer cytolysis. Proc Natl Acad Sci U S A 1997; 94: 11520-11525. (Pubitemid 27451031)
38. Hunt JS, Petroff MG, McIntire RH, Ober C,. HLA-G and immune tolerance in pregnancy. FASEB J 2005; 19: 681-693. (Pubitemid 40617373)
39. Forte P, Matter-Reissmann UB, Strasser M, Schneider MK, Seebach JD,. Porcine aortic endothelial cells transfected with HLA-G are partially protected from xenogeneic human NK cytotoxicity. Hum Immunol 2000; 61: 1066-1073. (Pubitemid 32043882)
40. Sasaki H, Xu XC, Mohanakumar T,. HLA-E and HLA-G expression on porcine endothelial cells inhibit xenoreactive human NK cells through CD94/NKG2-dependent and -independent pathways. J Immunol 1999; 163: 6301-6305.
41. Forte P, Pazmany L, Matter-Reissmann UB, et al. HLA-G inhibits rolling adhesion of activated human NK cells on porcine endothelial cells. J Immunol 2001; 167: 6002-6008. (Pubitemid 33062798)
42. Forte P, Baumann BC, Weiss EH, Seebach JD,. HLA-E expression on porcine cells: protection from human NK cytotoxicity depends on peptide loading. Am J Transplant 2005; 5: 2085-2093. (Pubitemid 41648455)
43. Lilienfeld BG, Crew MD, Forte P, Baumann BC, Seebach JD,. Transgenic expression of HLA-E single chain trimer protects porcine endothelial cells against human natural killer cell-mediated cytotoxicity. Xenotransplantation 2007; 14: 126-134. (Pubitemid 46457451)
44. Weiss EH, Lilienfeld BG, Muller S, et al. HLA-E/human beta2-microglobulin transgenic pigs: protection against xenogeneic human anti-pig natural killer cell cytotoxicity. Transplantation 2009; 87: 35-43.
45. Forte P, Lilienfeld BG, Baumann BC, Seebach JD,. Human NK cytotoxicity against porcine cells is triggered by NKp44 and NKG2D. J Immunol 2005; 175: 5463-5470. (Pubitemid 41456433)
46. Kiermeir D, Voegelin EBA, Ayares A, et al. Extracorporeal human blood perfusion of CD46 & HLA-E double transgenic pig limbs: a technique for the study of immunologic effects in composite tissue xenografts. Xenotransplantation 2011; 18: 304.
47. Abe M, Cheng J, Qi J, et al. Elimination of porcine hemopoietic cells by macrophages in mice. J Immunol 2002; 168: 621-628. (Pubitemid 34049561)
48. Basker M, Alwayn IP, Buhler L, et al. Clearance of mobilized porcine peripheral blood progenitor cells is delayed by depletion of the phagocytic reticuloendothelial system in baboons. Transplantation 2001; 72: 1278-1285. (Pubitemid 33026609)
49. Wu G, Korsgren O, Zhang J, et al. Pig islet xenograft rejection is markedly delayed in macrophage-depleted mice: a study in streptozotocin diabetic animals. Xenotransplantation 2000; 7: 214-220.
50. Andres A, Toso C, Morel P, et al. Macrophage depletion prolongs discordant but not concordant islet xenograft survival. Transplantation 2005; 79: 543-549. (Pubitemid 40365882)
51. Oldenborg PA, Zheleznyak A, Fang YF, et al. Role of CD47 as a marker of self on red blood cells. Science 2000; 288: 2051-2054. (Pubitemid 30397687)
52. Okazawa H, Motegi S, Ohyama N, et al. Negative regulation of phagocytosis in macrophages by the CD47-SHPS-1 system. J Immunol 2005; 174: 2004-2011. (Pubitemid 40223942)
53. Liu Y, Soto I, Tong Q, et al. SIRPbeta1 is expressed as a disulfide-linked homodimer in leukocytes and positively regulates neutrophil transepithelial migration. J Biol Chem 2005; 280: 36132-36140. (Pubitemid 41633885)
54. Motegi S, Okazawa H, Ohnishi H, et al. Role of the CD47-SHPS-1 system in regulation of cell migration. EMBO J 2003; 22: 2634-2644. (Pubitemid 36712361)
55. Ide K, Wang H, Tahara H, et al. Role for CD47-SIRPalpha signaling in xenograft rejection by macrophages. Proc Natl Acad Sci U S A 2007; 104: 5062-5066. (Pubitemid 47186176)
56. Barclay AN, Wright GJ, Brooke G, Brown MH,. CD200 and membrane protein interactions in the control of myeloid cells. Trends Immunol 2002; 23: 285-290. (Pubitemid 34628770)
57. Hatherley D, Barclay AN,. The CD200 and CD200 receptor cell surface proteins interact through their N-terminal immunoglobulin-like domains. Eur J Immunol 2004; 34: 1688-1694. (Pubitemid 39256051)
58. Wright GJ, Cherwinski H, Foster-Cuevas M, et al. Characterization of the CD200 receptor family in mice and humans and their interactions with CD200. J Immunol 2003; 171: 3034-3046. (Pubitemid 37093527)
59. Wang H, VerHalen J, Madariaga ML, et al. Attenuation of phagocytosis of xenogeneic cells by manipulating CD47. Blood 2007; 109: 836-842. (Pubitemid 46105989)
60. Blazar BR, Lindberg FP, Ingulli E, et al. CD47 (integrin-associated protein) engagement of dendritic cell and macrophage counterreceptors is required to prevent the clearance of donor lymphohematopoietic cells. J Exp Med 2001; 194: 541-549. (Pubitemid 32835048)
61. Tena A, Turcotte N, Leto-Barone AA, et al. Miniature swine expressing human CD47 to enhance bone marrow engraftment in non-human primates. Xenotransplantation 2011; 18: 271.
62. Gorczynski RM, Cattral MS, Chen Z, et al. An immunoadhesin incorporating the molecule OX-2 is a potent immunosuppressant that prolongs allo- and xenograft survival. J Immunol 1999; 163: 1654-1660. (Pubitemid 29352791)
63. Ekser B, Burlak C, Waldman JP, et al. Immunobiology of liver xenotransplantation. Expert Rev Clin Immunol 2012; 8: 621-634.
64. Londrigan SL, Sutherland RM, Brady JL, et al. In situ protection against islet allograft rejection by CTLA4Ig transduction. Transplantation 2010; 90: 951-957.
65. Martin C, Plat M, Nerriere-Daguin V, et al. Transgenic expression of CTLA4-Ig by fetal pig neurons for xenotransplantation. Transgenic Res 2005; 14: 373-384. (Pubitemid 41125388)
66. Phelps CJ, Ball SF, Vaught TD, et al. Production and characterization of transgenic pigs expressing porcine CTLA4-Ig. Xenotransplantation 2009; 16: 477-485.
67. Baehr A, van Buerck L, Kurome M, et al. LEA29Y transgenic pigs for overcoming cellular rejection in xenotransplantation. Xenotransplantation 2011; 18: 271.
68. Okazaki T, Honjo T,. The PD-1-PD-L pathway in immunological tolerance. Trends Immunol 2006; 27: 195-201.
69. del Rio ML, Penuelas-Rivas G, Dominguez-Perles R, et al. Antibody-mediated signaling through PD-1 costimulates T cells and enhances CD28-dependent proliferation. Eur J Immunol 2005; 35: 3545-3560. (Pubitemid 43025535)
70. Dong H, Zhu G, Tamada K, Chen L,. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 1999; 5: 1365-1369.
71. Latchman Y, Wood CR, Chernova T, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2001; 2: 261-268. (Pubitemid 33706004)
72. Mai G, del Rio ML, Tian J, et al. Blockade of the PD-1/PD-1L pathway reverses the protective effect of anti-CD40L therapy in a rat to mouse concordant islet xenotransplantation model. Xenotransplantation 2007; 14: 243-248. (Pubitemid 46699575)
73. Ding Q, Lu L, Zhou X, Zhou Y, Chou KY,. Human PD-L1-overexpressing porcine vascular endothelial cells induce functionally suppressive human CD4+CD25hiFoxp3+ Treg cells. J Leukoc Biol 2011; 90: 77-86.
74. Plege A, Borns K, Baars W, Schwinzer R,. Suppression of human T-cell activation and expansion of regulatory T cells by pig cells overexpressing PD-ligands. Transplantation 2009; 87: 975-982.
75. Chemnitz JM, Lanfranco AR, Braunstein I, Riley JL,. B and T lymphocyte attenuator-mediated signal transduction provides a potent inhibitory signal to primary human CD4 T cells that can be initiated by multiple phosphotyrosine motifs. J Immunol 2006; 176: 6603-6614. (Pubitemid 43787843)
76. del Rio ML, Kurtz J, Perez-Martinez C, et al. B- and T-lymphocyte attenuator targeting protects against the acute phase of graft versus host reaction by inhibiting donor anti-host cytotoxicity. Transplantation 2011; 92: 1085-1093.
77. Ishida Y, Agata Y, Shibahara K, Honjo T,. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 1992; 11: 3887-3895.
78. Maeda M, Carpenito C, Russell RC, et al. Murine CD160, Ig-like receptor on NK cells and NKT cells, recognizes classical and nonclassical MHC class I and regulates NK cell activation. J Immunol 2005; 175: 4426-4432. (Pubitemid 41361978)
79. Croft M,. The evolving crosstalk between co-stimulatory and co-inhibitory receptors: HVEM-BTLA. Trends Immunol 2005; 26: 292-294. (Pubitemid 40732659)